3 unchanged sentences
Stockholder Information
−Removed: As of March 2, 2023, there were approximately 232 shareholders of record of our common stock, which does not include stockholders that beneficially own shares held in a “nominee” or in “street” name, and six holders of record of Class C stock.
+Added: As of February 22, 2024, there were approximatel y 264 shar eholders of record of our common stock, which does not include stockholders that beneficially own shares held in a “nominee” or in “street” name, and six holders of record of Class C stock.
We have never declared or paid cash dividends on our common stock.
1 unchanged sentence
Our shares of Series A convertible preferred stock (the “PIPE Shares”), accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock.
+Added: To date, we have paid all preferred stock dividends in cash.
We currently intend to retain all remaining available funds and any future earnings to fund the development and growth of our business.
1 unchanged sentence
Issuer Purchases of Equity Securities
−Removed: Maximum Number (or
−Removed: Total Number of
−Removed: approximate dollar
+Added: Period Total Number
+Added: Purchased (1)
+Added: Average Price
+Added: Paid per Share Total Number of
Shares Purchased as
−Removed: value) of Shares
Part of Publicly
−Removed: that may yet be
−Removed: Average Price
Announced Plans or
+Added: Programs Maximum Number (or
+Added: approximate dollar
+Added: value) of Shares
+Added: that may yet be
Purchased Under the
−Removed: Purchased (1)
−Removed: Paid per Share
Plans or Programs
2 unchanged sentences
December 1 - December 31, 2023 1,865 $ 52.91 — $ —
+Added: Total 4,393 $ 52.56 —
(1) Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.
Performance Graph
−Removed: The graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Stock Market (US) Index, the Nasdaq Pharmaceuticals Index, and the S&P 600 Pharmaceuticals, Biotechnology & Life Sciences Index, assuming the investment of $100.00 on December 31, 2017, with dividends being reinvested.
+Added: The graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Stock Market (US) Index, and the S&P 600 Pharmaceuticals, Biotechnology & Life Sciences Index, assuming the investment of $100.00 on December 31, 2018, with dividends being reinvested.
The stock price performance in the graph below is not necessarily indicative of future price performance.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.